Ascendis Pharma A/S Reports Full Year 2016 Financial Results
(WorldNews Denmark)

COPENHAGEN, Denmark, March 22, 2017 /PRNewswire/ -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technology to address significant unmet medical needs in rare diseases, today announced financial results for the full year ended December 31, 2016. `2016 was a significant year for our company as we broadened our pipeline and pursued our vision to become a leading, integrated rare disease company with an initial focus on endocrinology,` said Jan Mikkelsen, Ascendis Pharma`s President and Chief Executive Officer. `We initiated the TransCon Growth Hormone Phase 3 heiGHt Trial in children with growth hormone deficiency (GHD). We also...